Summary
Max Jaderberg, president and founding team member of Isomorphic Labs, joins the No Priors podcast to discuss using AI to transform drug discovery. Isomorphic is backed by Alphabet and aims to solve all disease, building on the DeepMind research behind AlphaFold.
Jaderberg traces his path from a computer vision PhD that began before AlexNet, to selling a company to DeepMind in 2014, to working on early generative models and game-playing systems such as AlphaGo and AlphaStar. He describes AlphaFold as the first proof that a deep learning model could generalize in a meaningful area of biology, which led to the creation of Isomorphic in about 2021.
The conversation explains why most drug failures happen in the clinic, where toxicity and other problems appear only after patients are dosed. Jaderberg argues that predictive simulation models reaching experimental accuracy would let teams do far more design and iteration on a computer, so molecules entering the real world have a much higher chance of success. The hosts also dig into the roughly 15-year, $1.5 billion drug development pipeline and how much of it AI could realistically compress.
📺 Source: No Priors: AI, Machine Learning, Tech, & Startups · Published November 12, 2026
🏷️ Format: Interview
